Phase 3 Clinical Trial of CartiLife® in Korea
Phase 3
Active, not recruiting
- Conditions
- Articular Cartilage DegenerationArticular Cartilage Defect
- Interventions
- Drug: Autologous Chondrocyte Implantation (CartiLife®)Procedure: Microfracture Surgery
- First Posted Date
- 2021-09-21
- Last Posted Date
- 2022-05-17
- Lead Sponsor
- Biosolution Co., Ltd.
- Target Recruit Count
- 104
- Registration Number
- NCT05051332
- Locations
- 🇰🇷
Gangnam Severance Hospital, Seoul, Korea, Republic of
🇰🇷Chungnam National University Hospital, Daejeon, Korea, Republic of
🇰🇷Chosun University Hospital, Gwangju, Korea, Republic of
Phase 2 Clinical Trial of CartiLife® in the United States
Phase 2
Recruiting
- Conditions
- Articular Cartilage DegenerationArticular Cartilage Defect
- Interventions
- Drug: Autologous Chondrocyte Implantation (CartiLife®)
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2023-08-28
- Lead Sponsor
- Biosolution Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT04744402
- Locations
- 🇺🇸
Horizon Clinical Research, La Mesa, California, United States
🇺🇸Lafayette General Health, Lafayette, Louisiana, United States
🇺🇸Tilda Research, Irvine, California, United States
Study to Assess the Efficacy and Safety of Treatment of Articular Cartilage Lesions With CartiLife®
Phase 2
Completed
- Conditions
- Articular Cartilage Lesion of the Knee
- Interventions
- Drug: CartiLife®Procedure: Microfracture
- First Posted Date
- 2018-06-04
- Last Posted Date
- 2018-06-04
- Lead Sponsor
- Biosolution Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03545269
Study to Assess the Safety of Treatment of Articular Cartilage Lesions With CartiLife®
- First Posted Date
- 2018-05-07
- Last Posted Date
- 2018-05-07
- Lead Sponsor
- Biosolution Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT03517046
Clinical Efficacy and Safety of Autologous Cultured Keratinocyte Cell on Severe Burn Wood
Phase 3
- Conditions
- Burn Wound
- First Posted Date
- 2009-09-17
- Last Posted Date
- 2009-09-17
- Lead Sponsor
- Biosolution Co., Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT00978705
- Locations
- 🇰🇷
Hangang Sacred Heart Hospital, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath